Loading
Review of Case Materials
Reviews records, documents, testimony, data, and other relevant materials and consults with counsel regarding technical issues related to the matter.
Provide Expert Analysis
Applies specialized knowledge and experience to evaluate the technical or professional issues involved.
Form Expert Opinions
Develops independent, supportable opinions based on the available evidence and relevant standards.
Prepare Expert Reports
Showing Results 0 of 0
Breast cancers are routinely tested for estrogen receptor (ER), progesterone receptor (PR), and HER2 because these biomarkers help characterize the tumor and guide treatment selection. Hormone-receptor-positive cancers may respond to endocrine therapy, while HER2-positive cancers may be treated with HER2-targeted therapy. Biomarker status also contributes to prognostic staging and should be interpreted with tumor size, lymph-node involvement, distant spread, grade, and other clinical and pathological findings.
No. A mammogram may identify a mass, suspicious calcifications, architectural distortion, or another abnormality that warrants additional assessment, but imaging alone does not usually establish the pathological diagnosis of breast cancer. A biopsy provides cells or tissue for pathological examination and can determine whether cancer is present and, when applicable, characterize features such as invasive status, tumor type, grade, and biomarkers.
The surgical approach may depend on the size and distribution of the cancer relative to the breast, whether disease involves more than one area, prior breast or chest radiation, inflammatory breast cancer, genetic risk, ability to receive radiation, expected cosmetic outcome, and patient preferences. Lumpectomy, or breast-conserving surgery, is usually followed by radiation therapy, although selected patients may be treated differently. Mastectomy removes substantially more breast tissue, but radiation may still be recommended afterward depending on tumor and lymph-node findings.
No. Breast cancer can recur despite surgery, radiation, systemic therapy, or combinations of treatments that were appropriately selected and delivered. Analysis of recurrence may consider the original stage, lymph-node findings, grade, margins, tumor biology, treatment received, response to therapy, surveillance history, and the location and characteristics of the recurrent disease. ER, PR, or HER2 status can also differ when cancer recurs, so biopsy and repeat biomarker testing may provide clinically important new information.
Oncology, +4
Healthcare
Prepares clear, well-supported expert reports outlining methodology, analysis, findings, and opinions.
Provide Deposition Testimony
Explains findings and opinions under oath and responds to questioning during deposition testimony.
Testify in Court
Presents specialized findings and opinions clearly to judges, juries, arbitrators, or other decision-makers.
Treatment sequence depends on the stage, tumor biology, extent of disease, surgical considerations, and expected response to systemic therapy. Chemotherapy, HER2-targeted therapy, immunotherapy, or endocrine therapy may be given before surgery in selected patients, while others undergo surgery first followed by systemic treatment. Radiation commonly follows breast-conserving surgery and may also be used after mastectomy in selected cases, with its timing coordinated with chemotherapy and other treatments according to the treatment plan.
